

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 5, 2024

Standard BioTools Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-34180
(Commission
File Number)

77-0513190
(I.R.S. Employer
Identification No.)

2 Tower Place, Suite 2000
South San Francisco, California 94080
(Address of Principal Executive Offices) (Zip Code)

(650) 266-6000
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.001 per share	LAB	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On September 5, 2024, Standard BioTools Inc. (the “Company”) updated its investor presentation, which the Company expects to use in connection with general corporate presentations and will be made available on the Company’s website or distributed by the Company in hardcopy or electronic form. The investor presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference. The investor presentation is current as of September 5, 2024, and the Company disclaims any obligation to update the investor presentation after such date.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Investor Presentation issued by Standard BioTools Inc., dated September 5, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 5, 2024

STANDARD BIOTOOLS INC.

By: /s/ Michael Egholm, Ph.D.
Name: Michael Egholm, Ph.D.
Title: President and Chief Executive Officer



Unleashing Tools to Accelerate Breakthroughs in Human Health™

INVESTOR PRESENTATION
September 2024



Legal Information

Forward-looking statements

This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements other than statements of historical fact (including statements containing the words "believes," "plans," "anticipates," "expects," "estimates," "targets" and similar expressions) are statements that could be forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include statements regarding financial outlook and business performance, including related to revenues, growth, margin, and operating expenses; statements regarding future financial performance and expectations, operational strategic plans, deployment of capital, cash runway and sufficiency of cash resources, market and growth opportunity and potential, potential M&A activity, potential and ongoing restructuring plans; the potential to realize expected benefits following the merger with SomaLogic, Inc. ("SomaLogic"), our revenue outlook for the full year 2024, and our 2026 financial targets, including with respect to revenue, non-GAAP gross margin, non-GAAP profit, non-GAAP operating expenses, adjusted EBITDA, cash, and free cash flow; the competitive ability and position of the combined company, the success, cost and timing of the combined company's product development and marketing, and research and development activities, the combined company's ability to obtain and maintain regulatory approval for its products, the sufficiency of the combined company's cash, cash equivalents and investments to fund operations, and any assumptions underlying any of the foregoing. Statements regarding future events are based on the parties' current expectations and are necessarily subject to associated risks and uncertainties related to, among other things, the outcome of any legal proceedings related to the merger; risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized; risks that we may not realize expected cost savings from our restructuring plans, including the anticipated decrease in operational expenses, at the levels we expect; possible restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on our development activities and results of operation; restructuring activities, including asset sales, customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause us to use cash more quickly than we expect or change or curtail some of our plans, or both; risks that our expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons, such as changes in plans or actual events being different than our assumptions; our ability to achieve future financial targets; changes in our business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, our products; reliance on sales of capital equipment for a significant portion of our revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in our relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to our research and development activities, and distribution plans and capabilities; product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. For information regarding other related risks, see the "Risk Factors" section of our most recent annual report on Form 10-K filed with the SEC on March 1, 2024. We undertake no obligation to revise or update any forward-looking statements for any reason.

Non-GAAP financial information

Standard BioTools has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis. The non-GAAP financial measures included in this presentation are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company's core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company's core operating results. Management uses non-GAAP measures to compare the Company's performance relative to forecasts and strategic plans and to benchmark the company's performance externally against competitors. Non-GAAP information is not prepared in accordance with a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider the results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Trademarks

Standard BioTools, the Standard BioTools logo, Biomark, CyTOF, CyTOF XT, EPI, Helios, Hyperion, Hyperion+ and SomaScan are trademarks and/or registered trademarks of Standard BioTools Inc. (f.k.a. Fluidigm Corporation) and its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Executing on our Vision

Building a Diversified Life Science Tools Industry Leader



LEADING PLATFORMS AND TEAM

Leading Proteomics and Multi-omics Platforms

High content solutions in serum proteomics
spatial proteomics and single cell proteomics

Performance via SBS

Leveraging Standard BioTools Business
Systems (SBS) driving execution and profitability

Strategic M&A and Partnerships

Leveraging M&A and strategic partnerships (i.e. Illumina/
OEM partnerships) to expand sources of revenue

OPERATING AT SCALE

\$170-175MM

2024 Revenue Forecast

\$396MM

Cash, cash equivalents, and investments
(at 6/30/2024)

2026

Break-even adjusted EBITDA

Proven Leadership Team with Operational and Scientific Prowess



Michael Egholm, PhD
 Chief Executive Officer
Experience:

- Danaher
- Pall
- Roche



Alex Kim
 Chief Operating Officer &
 Interim Chief Financial Officer
Experience:

- Danaher
- Pall
- Milliken



Sean Mackay
 Chief Business Officer
Experience:

- IsoPlexis
- PhenomeX
- Lazard



Agnieszka Gall
 SVP, Chief Legal
Experience:

- Sandoz
- Alnylam
- GSK



Jeremy Davis
 Chief Commercial Officer
Experience:

- Danaher
- Culligan
- CG



Stephen Williams, MD PhD
 Chief Medical Officer
Experience:

- Somalogic
- Pfizer
- NIH



Betsy Jensen
 Chief H.R. Officer
Experience:

- Danaher
- Gibraltar
- ITW



David King, PhD
 SVP, Global R&D
Experience:

- IntegenX
- Affymetrix
- Guava



Mona Abou-Sayed
 SVP, SBS
Experience:

- Mitel
- Danaher
- Tektronix



Anders Davas
 SVP, Global Operations
Experience:

- Danaher
- Mölnlycke
- Telair

- Deep experience executing M&A and integration to drive profitability and growth
- Diversified life sciences tools and biopharma experience to drive progress and growth in critical end markets
- Deeply experienced multi-omic development team to provide innovation across all platform areas



Standard BioTools™

Our Four Proteomic & Multi-Omic Platforms Uniquely Scale

Our Solutions Cover the Four Sources of Critical Biomarker Information


Our M&A Strategy has delivered
four complementary platforms,
indexed to key biopharma needs

 **CYTOF™**

SINGLE CELL
PROTEOMICS

 **BIOMARK™**

GENOMICS/
MULTIOMICS



SOMASCAN™ 

PLASMA
PROTEOMICS

HYPERION™ 


SPATIAL
PROTEOMICS

Standard BioTools Product Leadership and Growth Drivers

PROTEOMICS PLATFORMS

MULTIOMICS PLATFORMS

SOMASCAN
PLASMA PROTEOME



800+

Clinical Publications

CYTOF
SINGLE CELL PROTEOMICS



2800+

Publications Utilizing Mass Cytometry

HYPERION
SPATIAL PROTEOMICS



2600+

Mass Cytometry Active User Base

BIOMARK
GENOMICS/ MULTIOMICS




9200+

Publications in Multiomics
and Genomics

illumina[®]
Proteomics Partnership
Standard BioTools™

Olink
OEM Proteomics Partnership

Our Proteomic Solutions are Key to the Highest Growth Therapeutic Areas



12,800+ proteomic and multiomic studies

SOMASCAN
PLASMA PROTEOME

HYPERION
SPATIAL PROTEOMICS

CYTOF
SINGLE CELL PROTEOMICS


BIOMARK
GENOMICS/ MULTIOMICS



Leading published clinical trial studies in below growth areas


3,937 Trials¹

Cardiometabolic, GLP-1s



15,755 Trials¹

Oncology



8,655 Trials¹

Immunology



¹ clinical trials database
Standard BioTools™

Our High Content Proteomics Uniquely Scale to Meet Customer Need

Widest coverage and consistency is driving our collective leadership in translational medicine

SOMASCAN PLASMA PROTEOME

Widest Coverage & Highest Precision

3x more proteins
vs ANTIBODY BASED APPROACH

<0.5x coefficient of variations (CVs)

CYTOF SINGLE CELL PROTEOMICS

Widest Coverage & Highest Multiplex

5-10x more functional proteins
vs FLOW

2x more markers

HYPERION SPATIAL PROTEOMICS


Widest Dynamic Range & Highest Throughput

10-15x more simultaneous markers
vs CYCLIC IMMUNOFLUORESCENCE

35-100x more throughput



High Content
Cardiometabolic
Biomarkers



High Content
Immuno-oncology
Biomarkers




High Content
Immuno-oncology
Biomarkers

Standard BioTools™

2024 Data: SomaScan is the Only Proteomic Approach that Scales

Greatest Precision Moat: SomaScan is the only plasma proteomics technology that scales




Rooney et al. Plasma proteomic comparisons change as coverage expands for SomaLogic and Olink. MedRxiv Preprint. 2024
Standard BioTools™

SomaScan Leadership in GLP-1 / Cardiometabolic and Key Growth Areas


Large studies, qualifying biomarkers, over 10 years create key moats

Novo Nordisk¹



Schattenberg et al. Journal of Hepatology 78:S811-S812. June 2023

Gilead¹



Kowdley et al. EASL June 2023

Greatest Study Moat: 10 years of major cardiometabolic and oncology studies sponsored by pharma companies such as Novo Nordisk, BMS, Gilead, etc. have driven efforts to significantly accelerate cardiometabolic trials

¹Listed firms are authors on Somascan studies
Standard BioTools™

Data Moat + Our Illumina Partnership Create Growth Opportunity


Integrating SomaLogic's products with Illumina's sequencing technologies, informatics toolsets and software

Illumina Partnership


Growth Opportunity



+



+



2000+
Installed base
of NovaSeq
Instruments

**Only Scalable
Solution on the
Market Today**

**Leading
Biomarker
Studies**


**Large proteomic translation
opportunity over the next deca**

Standard BioTools™



2024 Single Cell Proteomics & Spatial Proteomics Innovation



'24: Hyperion launch – with up to 100x throughput over other technologies



'22 CyTOF XT launch: Approaching walkaway operations



- ✓ KEYTRUDA (pembrolizumab)
- ✓ OPDIVO[†] (nivolumab)
- ✓ YERVOY[†] (ipilimumab)
- ✓ TECENTRIQ (atezolizumab)
- ✓ DARZALEX (daratumumab)

100% of the top 10 cancer immunotherapies have leveraged unique biomarkers in trials found by mass cytometry

1. Top cancer immunotherapies by revenue in 2023. [†]Therapies listed in peer reviewed publications Standard BioTools™

CyTOF Uniquely Scales with Critical Biomarkers for Oncology

Studies using conventional flow panels would have missed the critical differentiating markers

Conventional Panel in Spectral Fluorescence*

25 surface markers*

Additional Simultaneous Coverage only on CyTOF

+25 intracellular/functional markers



Biomarker for Identification of Drug Targets in MM Trial

BMS† | nivolumab

Predictive Biomarker of Response in Combination Nivo Phase 2 Trial

MERCK† | pembrolizumab

Predictive Biomarker of Survival in Pembro Phase 1 Trial


NOVARTIS† | CAR-T

Predictive Biomarker of Response in CAR-T

Unique Predictive Biomarker

*Competitor 25-color immunoprofiling assay †Pharma listed are the firms that manufacture and/ or market the therapies in the published studies
Standard BioTools™

Spatial Proteomics Scales in Dynamic Range, Multiplex, and Throughput



†Pharma listed are the firms that manufacture and/ or market the therapies in the published studies
Standard BioTools™

Standard BioTools Business System: Creates Flywheel Through M&A

SBS Practice	Impact
LEAN TRANSFORMATION Build awareness of opportunities to eliminate excess/ waste and achieve the best possible efficiency	GAIN OPERATING EFFICIENCY Reduce cost per unit, increase gross margins, and reduce operating cash use
CUSTOMER CENTRICITY Ensure delivering value to the customer is at the center of everything we do	CUSTOMER GROWTH Provide valuable proteomic and multi-omic solutions and insights to impact a growing customer base
KAIZEN CULTURE Facilitate continuous improvement (Kaizen) through standard work to ensure maximum quality and efficiency	GROW PROFITABLY Drive daily execution with quality systems, improving operational excellence around a leading suite of products



SBS

culture of continuous improvement to achieve world class operational excellence and exceptional customer value

Capturing \$80M Synergy Opportunity

Non-GAAP OpEx Reduction Expected to Reach \$80M in 2024



- Able to operationalize synergies ahead of schedule as initial target goal was to realize by YE 2024
- This preserves investments for future growth opportunities

Revenue

Continued Focus on Diversifying Revenue Mix

Pro Forma Combined	H1 2024	YOY
Instruments	\$12M	(32%)
Consumables	\$19M	(11%)
Service & Other	\$52M	(4%)
TOTAL	\$83M	(11%)

Pro Forma Combined	H1 2024	YOY
Proteomics (Px)	\$65M	(12%)
Genomics (Gx)	\$18M	(6%)
TOTAL	\$83M	(11%)

- YTD revenue declined due to continued pressure from macroeconomic headwinds
- SomaScan Assay services business down over 2023 driven primarily by the timing of large projects
- SomaScan Assay Kits business up over 2023 from continued expansion in authorized sites and related pull-through
- Illumina early access program underway and on track for 2025 f commercial release
- While macroeconomic conditions have continued to be a near-term headwind, our instrument revenue improved sequentially; pipeline remains robust/building
- Consumables and services in both Px and Gx impacted by prior year declines in legacy installed base; new installations expected to expand pull-through in late 2024 and beyond

Reflects combined historical information, assuming the merger closed on January 1, 2023. | Numbers may not add, and percentages may not foot due to rounding. All amounts presented are non-GAAP

Standard BioTools™

Gross Margin (Non-GAAP)

Executing Roadmap to Expanded Gross Margin Profile

Pro Forma Combined	Q2 2024	YoY	H1 2024	YoY
Non-GAAP Gross Profit \$	\$17M	(\$9M)	\$43M	(\$6M)
Non-GAAP Gross Margin %	45%	(840 bps)	51%	(124 bps)

- ~250 bps impact in Q2 from lower capacity utilization related to decrease in SomaScan assay services volumes
- ~300 bps impact in Q2 from strategic decisions to replace or upgrade instruments in the field

NON-GAAP GROSS MARGIN EXPANSION OPPORTUNITY

2026 Target GM Profile:

Mid 60%s

+ Continued deployment of SBS / Lean principles

+ Sales growth
+ Product mix shift

+ Overhead absorption
+ Reduced replacement and upgrade costs

Reflects combined historical information with certain adjustments, assuming the merger closed on January 1, 2023. | Non-GAAP gross margin excludes amortization of developed technology, non-cash stock-based compensation, and depreciation and amortization. Refer to Appendix for a reconciliation between GAAP and non-GAAP gross margin. | Numbers may not add, and percentages may not foot due to rounding. All amounts presented are non-GAAP

Standard BioTools™



Appendix

2024 Nature correction: SomaScan leads in precision/# of proteins

Section 1 and Figure 1 in BioRx preprint and Nature paper were both corrected

Article | [Open access](#) | Published: 04 October 2023

Large-scale plasma proteomics comparisons through genetics and disease associations

[Grimur Hjorleifsson Eldjarn](#), [Egil Ferkingstad](#), [Sigrun H. Lund](#), [Hannes Helgason](#), [Olafur Th. Magnusson](#), [Kristbjorg Gunnarsdottir](#), [Thorunn A. Olafsdottir](#), [Bjarni V. Halldorsson](#), [Pall I. Olason](#), [Florian Zink](#), [Sigurjon A. Gudjonsson](#), [Gardar Sveinbjornsson](#), [Magnus I. Magnusson](#), [Agnar Helgason](#), [Asmundur Oddsson](#), [Gisli H. Halldorsson](#), [Magnus K. Magnusson](#), [Saedis Saevarsdottir](#), [Thjodbjorg Eiriksdoottir](#), [Gisli Masson](#), [Hreinn Stefansson](#), [Ingileifur](#)


[Nature](#) 622, 348–357 (2023) | [DOI: 10.1038/s41586-023-04888-1](#)

56k Accesses | 3 Citations

[An Author](#)

[This article](#)

“Count” label misleading: not # of proteins measured




Author Correction | [Open access](#) | Published: 22 May 2024

Author Correction: Large-scale plasma proteomics comparisons through genetics and disease associations

[Grimur Hjorleifsson Eldjarn](#), [Egil Ferkingstad](#), [Sigrun H. Lund](#), [Hannes Helgason](#), [Olafur Th. Magnusson](#), [Kristbjorg Gunnarsdottir](#), [Thorunn A. Olafsdottir](#), [Bjarni V. Halldorsson](#), [Pall I. Olason](#), [Florian Zink](#), [Sigurjon A. Gudjonsson](#), [Gardar Sveinbjornsson](#), [Magnus I. Magnusson](#), [Agnar Helgason](#), [Asmundur Oddsson](#), [Gisli H. Halldorsson](#), [Magnus K. Magnusson](#), [Saedis Saevarsdottir](#), [Thjodbjorg Eiriksdoottir](#), [Gisli Masson](#), [Hreinn Stefansson](#), [Ingileifur](#)


[Nature](#) 622, 348–357 (2023) | [DOI: 10.1038/s41586-023-04888-1](#)

3388 Accesses | 1 Citation



High-Parameter Cell Analysis is a Challenge with Proteins

Mass cytometry solves fundamental limitation of fluorescence-based cell analysis




CytoTOF Uniquely Scales for Translational Research

The most robust solution in high-parameter flow cytometry market segment




SBI Advantage

No limit to how many different markers can be detected at once



Spatial Biology: Hyperion System is a Game-Changer



Standard BioTools™

*IF: immunofluorescence

SBI Advantage

40 Slides | 40 Markers
24 Hours



Non-GAAP Reconciliation

Gross Margin

	As Reported		Pro Forma	
	Q2 2024	Q2 2023	Q2 2024	Q2 2023
GAAP Gross Profit (\$M)	\$14.9	\$13.6	\$14.9	\$21.5
Add: Amortization of Acquired Intangible Assets	\$0.6	\$2.8	\$0.6	\$3.4
Add: Depreciation and Amortization in COGS	\$1.0	\$0.3	\$1.0	\$0.7
Add: Stock-Based Comp in COGS	\$0.3	\$0.1	\$0.3	\$0.2
Add: Restructuring in COGS	\$0.0	\$0.0	\$0.0	\$0.0
Add: Cost of Sales Adjustment	\$0.0	\$0.0	\$0.0	\$0.0
Non-GAAP Gross Profit	\$16.7	\$16.8	\$16.7	\$25.7
GAAP Gross Margin	40.1%	49.2%	40.1%	44.6%
Add: Amortization of Acquired Intangible Assets	1.5%	10.1%	1.5%	7.0%
Add: Depreciation and Amortization in COGS	2.6%	1.2%	2.6%	1.5%
Add: Stock-Based Comp in COGS	0.8%	0.4%	0.8%	0.3%
Add: Restructuring in COGS	0.0%	0.0%	0.0%	0.0%
Add: Cost of Sales Adjustment	0.0%	0.0%	0.0%	0.0%
Non-GAAP Gross Margin	45.0%	60.9%	45.0%	53.4%

Figures are derived from Condensed Consolidated Statements of Operations as reported in the Company's Reports on Form 10-Q for the relevant periods. | Numbers may not add, and percentages may not foot due to rounding.

Standard BioTools™

Non-GAAP Reconciliation - YTD

Gross Margin

	As Reported		Pro Forma	
	Q2 YTD 2024	Q2 YTD 2023	Q2 YTD 2024	Q2 YTD 2023
GAAP Gross Profit (\$M)	\$39.1	\$25.9	\$37.7	\$41.8
Add: Amortization of Acquired Intangible Assets	\$2.5	\$5.6	\$2.5	\$6.7
Add: Depreciation and Amortization in COGS	\$2.0	\$0.7	\$2.0	\$1.4
Add: Stock-Based Comp in COGS	\$0.5	\$0.5	\$0.5	\$0.6
Add: Restructuring in COGS	\$0.0	\$0.0	\$0.0	\$0.0
Add: Cost of Sales Adjustment	(\$1.8)	\$0.0	\$0.0	(\$1.3)
Non-GAAP Gross Profit	\$42.3	\$32.6	\$42.7	\$49.1
GAAP Gross Margin	47.2%	49.0%	45.2%	44.6%
Add: Amortization of Acquired Intangible Assets	3.0%	10.6%	3.0%	7.2%
Add: Depreciation and Amortization in COGS	2.4%	1.2%	2.4%	1.5%
Add: Stock-Based Comp in COGS	0.6%	0.9%	0.6%	0.6%
Add: Restructuring in COGS	0.0%	0.0%	0.0%	0.0%
Add: Cost of Sales Adjustment	(2.2%)	0.0%	0.0%	(-1.4%)
Non-GAAP Gross Margin	51.1%	61.7%	51.2%	52.5%

Figures are derived from Condensed Consolidated Statements of Operations as reported in the Company's Reports on Form 10-Q for the relevant periods. | Numbers may not add, and percentages may not foot due to rounding.

Standard BioTools™